BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 19486002)

  • 1. Romiplostim-induced erythromelalgia in a patient with idiopathic thrombocytopenic purpura.
    Kluger N; Bessis D; Quittet P; Rigau V; Guillot B; Girard C
    Br J Dermatol; 2009 Aug; 161(2):482-4. PubMed ID: 19486002
    [No Abstract]   [Full Text] [Related]  

  • 2. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura.
    Dultz G; Kronenberger B; Azizi A; Mihm U; Vogl TJ; Sarrazin U; Sarrazin C; Zeuzem S; Hofmann WP
    J Hepatol; 2011 Jul; 55(1):229-32. PubMed ID: 21310200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emperipolesis in a patient receiving romiplostim.
    Cooper N; Bain BJ
    Am J Hematol; 2016 Jan; 91(1):166. PubMed ID: 26407183
    [No Abstract]   [Full Text] [Related]  

  • 4. Extensive cerebral venous sinus thrombosis after romiplostim treatment for immune thrombocytopenia (ITP) despite severe thrombocytopenia.
    Ho P; Khan S; Crompton D; Hayes L
    Intern Med J; 2015 Jun; 45(6):682-3. PubMed ID: 26059883
    [No Abstract]   [Full Text] [Related]  

  • 5. Romiplostim-induced myelofibrosis.
    Rashidi A; Roullet MR
    Blood; 2013 Sep; 122(12):2001. PubMed ID: 24175353
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia.
    Leung T; Lokan J; Turner P; Smith C
    Pathology; 2011 Aug; 43(5):520-2. PubMed ID: 21753725
    [No Abstract]   [Full Text] [Related]  

  • 7. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of romiplostim myelofibrosis to myeloproliferative neoplasm.
    Dadfarnia T; Lee S
    Blood; 2014 Mar; 123(13):1987. PubMed ID: 24800303
    [No Abstract]   [Full Text] [Related]  

  • 9. Leukaemic transformation with romiplostim.
    Gardner K; Mathe S; Sahu S
    Br J Haematol; 2012 Jul; 158(2):153. PubMed ID: 22702968
    [No Abstract]   [Full Text] [Related]  

  • 10. [Development of thrombopoietin receptor agonists].
    Miyakawa Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract]   [Full Text] [Related]  

  • 11. Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura.
    Gardiner EE; Thom JY; Al-Tamimi M; Hughes A; Berndt MC; Andrews RK; Baker RI
    Br J Haematol; 2010 May; 149(4):625-8. PubMed ID: 20148887
    [No Abstract]   [Full Text] [Related]  

  • 12. The road to romiplostim approval and beyond.
    Lyman GH
    Oncology (Williston Park); 2009 Jul; 23(8):709-10, 715. PubMed ID: 19711586
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombopoietin mimetics for systemic lupus erythematosus with antiphospholipid antibodies should be discussed separately.
    Kanda M; Atsumi T
    Lupus; 2018 Oct; 27(11):1876-1877. PubMed ID: 29958500
    [No Abstract]   [Full Text] [Related]  

  • 14. Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies.
    Cheloff AZ; Al-Samkari H
    Platelets; 2022 Nov; 33(8):1312-1313. PubMed ID: 36050822
    [No Abstract]   [Full Text] [Related]  

  • 15. Romiplostim for the early management of severe immune thrombocytopenia unresponsive to conventional treatment.
    Tagariello G; Sartori R; Radossi P; Maschio N; Risato R; Stasi R
    Br J Haematol; 2012 Apr; 157(2):256-8. PubMed ID: 22111882
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531).
    Pullarkat VA; Gernsheimer TB; Wasser JS; Newland A; Guthrie TH; de Wolf JT; Stewart R; Berger D
    Am J Hematol; 2009 Aug; 84(8):538-40. PubMed ID: 19569197
    [No Abstract]   [Full Text] [Related]  

  • 17. Response of refractory immune thrombocytopenia after bone marrow transplantation to romiplostim.
    Beck JC; Burke MJ; Tolar J
    Pediatr Blood Cancer; 2010 Mar; 54(3):490-1. PubMed ID: 19908296
    [No Abstract]   [Full Text] [Related]  

  • 18. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option.
    Prescrire Int; 2010 Feb; 19(105):15. PubMed ID: 20455333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet production bolstered with romiplostim approval.
    Morrow T
    Manag Care; 2008 Oct; 17(10):49-50. PubMed ID: 18990926
    [No Abstract]   [Full Text] [Related]  

  • 20. Romiplostim: new drug. Thrombocytopenic purpura: for selected patients, with close monitoring.
    Prescrire Int; 2009 Dec; 18(104):246. PubMed ID: 20020571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.